Table 2 Baseline parameters of the study

All patients

80

118

42

156

75

123

Gender, n (%)

Male

60 (30.3%)

94 (47.5%)

0.549

29 (14.6%)

125 (63.1%)

0.185

59 (29.8%)

95 (48%)

0.953

Female

20 (10.1%)

24 (12.1%)

13 (6.6%)

31 (15.7%)

16 (8.1%)

28 (14.1%)

Age n (%)

 > 60

31 (15.7%)

42 (21.2%)

0.763

16 (8.1%)

57 (28.8%)

0.996

30 (15.2%)

43 (21.7%)

0.575

 ≤ 60

49 (24.7%)

76 (38.4%)

26 (13.1%)

99 (50%)

45 (22.7%)

80 (40.4%)

Fuhrman grade, n (%)

G1 + G2

41 (20.7%)

67 (33.8%)

0.534

21 (10.6%)

87 (43.9%)

0.623

36 (18.2%)

72 (36.4%)

0.195

G3 + G4

39 (19.7%)

51 (25.8%)

21 (10.6%)

69 (34.8%)

39 (19.7%)

51 (25.8%)

Targeted therapy, n (%)

Absent

18 (9.1%)

17 (8.6%)

0.275

5 (2.5%)

30 (15.2%)

0.535

15 (7.6%)

20 (10.1%)

0.796

TK1

11 (5.6%)

14 (7.1%)

6 (3%)

19 (9.6%)

9 (4.5%)

16 (8.1%)

PD1

51 (25.8%)

87 (43.9%)

31 (15.7%)

107 (54%)

51 (25.8%)

87 (43.9%)

Tumor site, n (%)

Left

51 (25.8%)

69 (34.8%)

0.550

28 (14.1%)

92 (46.5%)

0.467

45 (22.7%)

75 (37.9%)

1.000

Right

29 (14.6%)

49 (24.7%)

14 (7.1%)

64 (32.3%)

30 (15.2%)

48 (24.2%)

Number of metastatic sites, n (%)

 < 2

55 (27.8%)

96 (48.5%)

0.061

30 (15.2%)

121 (61.1%)

0.532

56 (28.3%)

95 (48%)

0.810

 ≥ 2

25 (12.6%)

22 (11.1%)

12 (6.1%)

35 (17.7%)

19 (9.6%)

28 (14.1%)

Histology, n (%)

Clear cell

70 (35.4%)

106 (53.5%)

0.778

36 (18.2%)

140 (70.7%)

0.422

69 (34.8%)

107 (54%)

0.393

Non–clear cell

10 (5.1%)

12 (6.1%)

6 (3%)

16 (8.1%)

6 (3%)

16 (8.1%)

Microvascular invasion, n (%)

Present

23 (11.6%)

24 (12.1%)

0.232

14 (7.1%)

33 (16.7%)

0.149

21 (10.6%)

26 (13.1%)

0.353

Absent

57 (28.8%)

94 (47.5%)

28 (14.1%)

123 (62.1%)

54 (27.3%)

97 (49%)

Tumor size (cm), n (%)

 > 7

41 (20.7%)

75 (37.9%)

0.114

21 (10.6%)

95 (48%)

0.273

39 (19.7%)

77 (38.9%)

0.187

 ≤ 7

39 (19.7%)

43 (21.7%)

21 (10.6%)

61 (30.8%)

36 (18.2%)

46 (23.2%)

Nephrectomy, n (%)

Minimally

invasive

73 (36.9%)

103 (52%)

0.522

39 (19.7%)

137 (69.2%)

0.579

68 (34.3%)

108 (54.5%)

0.698

Open

7 (3.5%)

15 (7.6%)

3 (1.5%)

19 (9.6%)

7 (3.5%)

15 (7.6%)

T stage, n (%)

T1 + T2

13 (6.6%)

41 (20.7%)

0.007

6 (3%)

48 (24.2%)

0.053

19 (9.6%)

35 (17.7%)

0.754

T3 + T4

67 (33.8%)

77 (38.9%)

36 (18.2%)

108 (54.5%)

56 (28.3%)

88 (44.4%)

N stage, n (%)

N0

57 (28.8%)

90 (45.5%)

0.531

29 (14.6%)

118 (59.6%)

0.504

50 (25.3%)

97 (49%)

0.083

N1

23 (11.6%)

28 (14.1%)

13 (6.6%)

38 (19.2%)

25 (12.6%)

26 (13.1%)

Tumor necrosis, n (%)

Present

43 (21.7%)

55 (27.8%)

0.400

27 (13.6%)

71 (35.9%)

0.047

43 (21.7%)

55 (27.8%)

0.115

Absent

37 (18.7%)

63 (31.8%)

15 (7.6%)

85 (42.9%)

32 (16.2%)

68 (34.3%)